Meng Jiao Jiang
Chief Executive Officer at C-Bridge Capital Investment Management Ltd.
Profile
Meng has over 18 years of investment, M&A and investment banking experience.
She has been at CBC Group since the beginning in early 2014, and has led investments in the pharmaceutical sector, including CMAB, I-MAB, and Innovent, among others.
Meng spearheaded the launch of the firm’s Venture Capital strategy, which she currently heads.
Prior to CBC Group, Meng was most recently Director/COO at Far East Horizon’s Investments Group where she was responsible for department operations, risk management, and establishing and implementing budgets.
For two years, Meng led teams on M&A and minority healthcare services investments.
Prior to joining Far East Horizon, Meng was Managing Director at ARC China, where she established its China operations and headed various investments across multiple sectors.
Before her time at ARC China, Meng was an Associate Director at Business Development Asia in Shanghai where she executed numerous joint ventures, acquisition and divestiture transactions in the chemical, consumer, and manufacturing sectors in China and Japan.
Meng started her career at UBS Investment Bank in New York, where she worked on origination and execution of M&A, IPO, Debt and Equity issuances.
Meng graduated with Honours in Economics and Political Science from Wellesley College.
Meng Jiao Jiang active positions
| Companies | Position | Start |
|---|---|---|
I-Mab Bio-tech (Tianjin) Co. Ltd.
 I-Mab Bio-tech (Tianjin) Co. Ltd. BiotechnologyHealth Technology I-Mab Bio-tech (Tianjin) Co., Ltd. engages in the research and development of medicine and biological products. Its business activities include investment information consultation, and health information services. The company was founded on April 19, 2012 and is headquartered in Tianjin, China. | Director/Board Member | - |
CMAB BioPharma (Suzhou) Inc.
 CMAB BioPharma (Suzhou) Inc. Miscellaneous Commercial ServicesCommercial Services CMAB BioPharma (Suzhou) Inc. develops and manufactures biological products. Its services include process development, GMP manufacturing, aseptic drug and quality development. The company was founded by Qibin Liang in June 2017 and is headquartered in Suzhou, China. | Chairman | - |
Nuance Pharma (Shanghai) Co., Ltd.
 Nuance Pharma (Shanghai) Co., Ltd. Pharmaceuticals: MajorHealth Technology Nuance Pharma (Shanghai) Co., Ltd. is a Chinese innovation-focused biopharmaceutical company founded in 2014 by Yi Bo Shao and Mark Gavin Lotter. The company is based in Shanghai, China, and has subsidiaries in Germany and China. Nuance Pharma's mission is to address critical unmet medical needs in the Pacific region. The company has a differentiated combination of commercial stage and innovative pipeline assets across respiratory, pain management, emergency care, and iron deficiency anemia. Nuance Pharma deploys the dual wheel model that incubates a late clinical stage innovative portfolio while maintaining a self-sustainable commercial operation. The company has assembled a portfolio of promising clinical-stage drug candidates for respiratory, pain, and iron deficiency anemia. Nuance Pharma's world-class clinical and regulatory teams, visionary approach to business development, and integrated commercial platforms enable the company to continuously accelerate the access of innovative treatments to patients. | Director/Board Member | 2020-08-04 |
| C-Bridge Capital Investment Management Ltd. | Chief Executive Officer | 2013-12-31 |
Former positions of Meng Jiao Jiang
| Companies | Position | End |
|---|---|---|
| FAR EAST HORIZON LIMITED | Director/Board Member | 2013-11-30 |
ARC China, Inc. (China)
 ARC China, Inc. (China) Investment ManagersFinance Part of ARC China Holdings Ltd., ARC China, Inc. is a financial investment firm based in Shanghai, China. The Chinese company provides financial investment services. | Chief Executive Officer | 2011-05-31 |
| CHINA ENERGY RECOVERY, INC. | Director/Board Member | 2009-09-30 |
| Shanghai Kangshiqiao Business Consulting Co. Ltd. | Private Equity Investor | - |
Affamed Therapeutics (Us), Inc.
 Affamed Therapeutics (Us), Inc. Pharmaceuticals: MajorHealth Technology Part of AffaMed Therapeutics, Affamed Therapeutics (US), Inc. is a clinical stage biopharmaceutical company based in New York, NY. The private company focuses on developing and commercializing pharmaceutical, digital, and surgical products to address critical unmet medical needs in ophthalmological, neurological, and psychiatric disorders for patients worldwide. The CEO of the company is Dayao Zhao. | Director/Board Member | - |
Training of Meng Jiao Jiang
| Wellesley College | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| CHINA ENERGY RECOVERY, INC. | Industrial Services |
| FAR EAST HORIZON LIMITED | Finance |
| I-MAB | Health Technology |
| Private companies | 11 |
|---|---|
Clarus Therapeutics, Inc.
 Clarus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Clarus Therapeutics, Inc. operated as a men's health specialty pharmaceutical company that focuses on the development and commercialization of oral testosterone replacement therapy. It offered JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company was founded by Robert E. Dudley in February 2004 and was headquartered in Northbrook, IL. | Health Technology |
ARC Investment Partners LLC
 ARC Investment Partners LLC Financial ConglomeratesFinance ARC Investment Partners LLC operates as a private equity firm. The company was founded by Adam Mike Roseman and Scott Jenkinsand and is headquartered in Beverly Hilss, CA. | Finance |
BDA Partners, Inc.
 BDA Partners, Inc. Miscellaneous Commercial ServicesCommercial Services BDA Partners, Inc. provides financial consulting services. It offers advise on acquisitions, divestments, joint ventures and other forms of strategic alliances. The company was founded by Euan Rellie and Charles Maynard in 1996 and is headquartered in New York, NY. | Commercial Services |
UBS Investment Bank (US)
 UBS Investment Bank (US) Investment Banks/BrokersFinance UBS Investment Bank provides investment banking and securities brokerage services. Its clients include institutional and corporate clients, intermediaries, governments, and hedge funds. The firm also provides merger and acquisition advisory, private placement, investment research, foreign exchange, equity, and leverage finance advisory services. The firm is headquartered in San Francisco, CA. | Finance |
I-Mab Bio-tech (Tianjin) Co. Ltd.
I-Mab Bio-tech (Tianjin) Co. Ltd. BiotechnologyHealth Technology I-Mab Bio-tech (Tianjin) Co., Ltd. engages in the research and development of medicine and biological products. Its business activities include investment information consultation, and health information services. The company was founded on April 19, 2012 and is headquartered in Tianjin, China. | Health Technology |
ARC China, Inc. (China)
ARC China, Inc. (China) Investment ManagersFinance Part of ARC China Holdings Ltd., ARC China, Inc. is a financial investment firm based in Shanghai, China. The Chinese company provides financial investment services. | Finance |
CMAB BioPharma (Suzhou) Inc.
CMAB BioPharma (Suzhou) Inc. Miscellaneous Commercial ServicesCommercial Services CMAB BioPharma (Suzhou) Inc. develops and manufactures biological products. Its services include process development, GMP manufacturing, aseptic drug and quality development. The company was founded by Qibin Liang in June 2017 and is headquartered in Suzhou, China. | Commercial Services |
| Shanghai Kangshiqiao Business Consulting Co. Ltd. | Finance |
Nuance Pharma (Shanghai) Co., Ltd.
Nuance Pharma (Shanghai) Co., Ltd. Pharmaceuticals: MajorHealth Technology Nuance Pharma (Shanghai) Co., Ltd. is a Chinese innovation-focused biopharmaceutical company founded in 2014 by Yi Bo Shao and Mark Gavin Lotter. The company is based in Shanghai, China, and has subsidiaries in Germany and China. Nuance Pharma's mission is to address critical unmet medical needs in the Pacific region. The company has a differentiated combination of commercial stage and innovative pipeline assets across respiratory, pain management, emergency care, and iron deficiency anemia. Nuance Pharma deploys the dual wheel model that incubates a late clinical stage innovative portfolio while maintaining a self-sustainable commercial operation. The company has assembled a portfolio of promising clinical-stage drug candidates for respiratory, pain, and iron deficiency anemia. Nuance Pharma's world-class clinical and regulatory teams, visionary approach to business development, and integrated commercial platforms enable the company to continuously accelerate the access of innovative treatments to patients. | Health Technology |
| C-Bridge Capital Investment Management Ltd. | |
Affamed Therapeutics (Us), Inc.
Affamed Therapeutics (Us), Inc. Pharmaceuticals: MajorHealth Technology Part of AffaMed Therapeutics, Affamed Therapeutics (US), Inc. is a clinical stage biopharmaceutical company based in New York, NY. The private company focuses on developing and commercializing pharmaceutical, digital, and surgical products to address critical unmet medical needs in ophthalmological, neurological, and psychiatric disorders for patients worldwide. The CEO of the company is Dayao Zhao. | Health Technology |
- Stock Market
- Insiders
- Meng Jiao Jiang
